The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This dual-therapy targets a pathway ...

Novel weapons to counter endocrine therapy resistance and treat progressive disease ...

PsiThera, formerly Psivant Therapeutics, raised just over $47 million for oral drugs targeting “diseases long-constrained by ...

Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.

Daiichi Sankyo continues to advance its pipeline, offering positive catalysts over the next year. Click here to read why ...

Daiichi Sankyo showcases strength of industry-leading ADC portfolio with latest research updates from five landmark breast cancer trials at SABCS: Tokyo Tuesday, December 9, 2025, ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Bayer’s menopause drug, Lynkuet, received a recommendation for approval from the European Medicines Agency (EMA), moving it ...

Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options, highlighting the latest advancements in ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class ...

(MENAFN- GlobeNewsWire - Nasdaq) The market opportunities for TROP-2-targeted immunotherapies are significant, with high Trop-2 expression in multiple aggressive cancers like breast and bladder..

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of TROP-2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about ...